- Home
- RLMD vs JGH Comparison
RLMD vs JGH Comparison
Compare RLMD & JGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLMD | JGH |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.0M | 292.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RLMD | JGH |
|---|---|---|
| Price | $4.38 | $12.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.50 | N/A |
| AVG Volume (30 Days) | ★ 978.5K | 73.9K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.85% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $10.36 |
| 52 Week High | $5.12 | $12.85 |
Technical Indicators
Market Signals| Indicator | RLMD | JGH |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 52.68 |
| Support Level | $4.28 | $12.55 |
| Resistance Level | $4.75 | $12.61 |
| Average True Range (ATR) | 0.39 | 0.07 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 39.11 | 72.72 |
Price Performance
Historical ComparisonAbout RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.